INTRODUCTION
The cause of Parkinson's disease is not known, yet it is associated with the progressive death of dopaminergic (DA) neurons, inducing motor impairment. The characteristic symptoms of Parkinson's disease appear when up to 70% of DA nigrostriatal neurons have degenerated. There is currently no satisfactory cure for this disease. Symptomatic treatment of the diseaseassociated motor impairments involves oral administration of L-DOPA. L-DOPA is transported across the blood-brain barrier and converted to dopamine, partly by residual DA neurons, leading to a substantial improvement of motor function. However, after a few years, the degeneration of DA neurons progresses, the effects of L-DOPA are reduced, and side effects appear (Marsden and Parkes, 1976) . Better therapy of Parkinson's disease is therefore desirable. Both rodent and nonhuman primate animal models have been developed for testing new therapeutic approaches, and the rat models of Parkinson's disease are particularly convenient (Ungerstedt and Arbuthnott, 1970; Sauer and Oertel, 1994) . Models with complete or partial lesion of substantia nigra (SN) DA neurons have been developed. In the complete lesion model, the animals are given an injection of 6-hydroxydopamine (6-OHDA) unilaterally into the ascending mesostriatal pathway originating from the DA neurons of the SN (A9) and the mesostriatal pathway originating from the DA neurons located near the ventral tegmental area (A10). This causes a complete lesion of SN DA neurons and a complete denervation of the ipsilateral striatum from its DA afferents (Ungerstedt and Arbuthnott, 1970) . In the partial lesion model, the animals are given an injection of 6-OHDA unilaterally into their striatum. This causes a partial lesion of SN DA neurons and partially denervates the ipsilateral striatum from its DA afferents and this degeneration occurs progressively (Sauer and Oertel, 1994) .
